Asthma
Conditions
Interventions
azithromycin group:receive azithromycin
Sponsors
Institute of Respiratory Diseases, the Second Affiliated Hospital of Third Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Screening criteria: 1.Informed consent; 2. between the ages of 18 and 75 years of age , including 18 and 75; 3. have recurrent episodes of wheezing , shortness of breath , chest tightness or cough and other symptoms; 4. Asthma diagnosed more than 3 months by bronchodilation test or challenge test positive; 5. ACT score 65%, Eos 65%, Eos <3%; 2. Screening period, showing good compliance, with the completion of the study are expected to be.
Exclusion criteria
Exclusion criteria: Screening criteria: 1. Regular ICS therapy is being used (regular is defined as: the use of time greater than one month and medication compliance > 80%); 2. Systemic hormone therapy or unknown oral asthma medications being regular used; 3. Respiratory infection; 4.moderate and moderate to severe acute exacerbation; 5. Allergy to macrolide antibiotics or placebo; 6. can not stop ergot derivatives, rifabutin, propylthiouracil, non-steroidal anti-inflammatory drugs, phenytoin, card carbamazepine during treatment; 7. combined with other lung diseases such as COPD, bronchiectasis, lung cancer; 8. existence of serious complications; 9. other unsuitable participate in the trial of the case (such as pregnancy, breast-feeding, do not have the legal capacity etc.). Random criteria: 1. Signs of respiratory infection during screening period; 2. Imaging, laboratory results of visit one suggest that respiratory tract infection or clinically significant abnormalities; 3.moderate and moderate exacerbations during screening period; 4. oral or intravenous use of systemic hormone therapy during screening period; 5. within (whichever is longer) 5 plasma half-life from random used antibiotic treatment or other study drug; 6. allergic for basic treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| interleukin-17;interleukin-1ß;interleukin-6; | — |
Secondary
| Measure | Time frame |
|---|---|
| interleukin-23;CRP;induced sputum cytology;Forced expiratory volume in one second %predicted;Asthma control test;Peripheral blood leukocyte count;interleukin-8;Neutrophil elastase; | — |
Countries
China
Contacts
Public ContactChangzheng Wang
Institute of Respiratory Diseases, the Second Affiliated Hospital of Third Military Medical University. Chongqing
Outcome results
None listed